Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
Type I interferons and SARS-CoV-2: from cells to organisms
Paul Bastard et al. Curr Opin Immunol. 2022.
https://pubmed.ncbi.nlm.nih.gov/35149239/
Abstract
Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro produce low levels of type I IFNs, and SARS-CoV-2 proteins can inhibit various steps in type I IFN production and response. Exogenous type I IFNs inhibit viral growth in vitro. In various animal species infected in vivo, type I IFN deficiencies underlie higher viral loads and more severe disease than in control animals. The early administration of exogenous type I IFNs improves infection control. In humans, inborn errors of, and auto-antibodies against type I IFNs underlie life-threatening COVID-19 pneumonia. Overall, type I IFNs are essential for host defense against SARS-CoV-2 in individual cells and whole organisms.
Pretty much as good as it can get..
3rd time!
https://twitter.com/novacytgroup/status/1480593537515327490?s=21
Tweeted again. Am I missing something?
https://twitter.com/novacytgroup/status/1480592795328991238?s=21
LFT Our PathFlow® #LFT is designed to detect the presence of SARS-CoV-2, which includes the identification of the #Omicron #variant. Contact us for immediate delivery: enquiries.microgen@novacyt.com #Novacyt #COVID19 #VariantofConcern #diagnosis
https://twitter.com/novacytgroup/status/1480590268663541766?s=21
As Antiviral Pills Arrive, Can Testing Keep Up?
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
https://www.nytimes.com/2021/11/29/health/covid-pill.html
Please don’t get hung up on Activ-2 progression.
Sprinter P3 is the main event. The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.
Wait, add/hold be patient!!!
I agree, I’ll be voting against.